你会注射中国疫苗吗？

[gzhou8888]

不会

 

[寻源思远]

非紧急需要，不会考虑。

 

[carnegie]

一定不會 , 過不了信心這關 !!

 

[AZURR]

@SLS 很不谨慎啊。疫苗弄不好，毒性不比病毒差。你接触病毒的概率是千分之一万分之一，疫苗打进去就是100%。别说中国疫苗，就是加拿大出了疫苗我也不会急着打。

 

[soleil_lee－太阳李]

不会，长春生物，武汉生化所假疫苗不要太多。

 

[cath]

The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19
From: National Research Council Canada

News release
One of only a handful of vaccine candidates currently in human clinical trials in the world to begin initial evaluation in Canada
May 12, 2020 – Montréal, Quebec – National Research Council of Canada
The National Research Council of Canada (NRC) today announced a collaboration with CanSino Biologics Inc. (CanSinoBIO) to advance bioprocessing and clinical development in Canada of a candidate vaccine against COVID-19.
Referred to as Ad5-nCoV, the vaccine candidate received Chinese regulatory approval earlier this year, allowing CanSino Biologics to move ahead with human clinical trials in China. It is one of only a handful of vaccine candidates in the world against COVID-19 so far approved for initial safety testing in humans, and was the first candidate vaccine to begin conducting Phase II human clinical trials.
The relationship between the NRC and CanSinoBIO was first established in 2013. The NRC’s HEK293 cell line was later licensed to CanSinoBIO and used in the development of an approved vaccine against the Ebola virus. The new COVID-19 vaccine is also produced using HEK293 cell lines that were designed and developed at the NRC. By bringing their respective technologies and expertise together to fight COVID-19, CanSino Biologics and the NRC are aiming to pave the way for future clinical trials in Canada, in collaboration with the Canadian Immunization Research Network at the Canadian Center for Vaccinology. The vaccine is subject to approval by Health Canada, for which CanSinoBIO is in the process of filing a Clinical Trial Application (CTA).
This collaboration will allow the NRC to advance a scale-up production process for the vaccine candidate, using its proprietary HEK293 cell line. As a preparatory step, the Government of Canada has already announced $44 million in funding to support upgrades to the NRC’s facilities in Montreal to enable compliance with Good Manufacturing Practice (GMP) standards, to ensure readiness for Canadian bioprocessing of potential vaccine candidates as they become available.
Quotes

“This vaccine candidate holds great promise. Until such time as there is an effective vaccine for COVID-19, the virus will continue to disrupt all aspects of our society and economy. The NRC is proud of our ongoing partnership with CanSino Biologics, and we are working hard to achieve success in this vital new collaboration.”
– Mr. Iain Stewart, President of the National Research Council of Canada

“We’ve been in a committed partnership with the NRC for almost a decade. It is perfect timing to leverage cutting-edge technology and resources from both sides that are critical to the development of Ad5-nCoV. We are in this global public health emergency together, and a collaborative engagement could be the shortcut to help win this race against novel coronavirus disease. CanSino Biologics has strong connections to Canada, and we’re proud to be building on past successes and continuing our ongoing partnership with the NRC to address health needs on a global scale.”
– Dr. Xuefeng Yu, Chairman and CEO of CanSino Biologics Inc.

Quick facts

• The vaccine candidate, Ad5-nCoV, was developed using technology from both China and Canada. It was co-developed by the Beijing Institute of Biotechnology (BIB) and CanSino Biologics Inc. using a genetically engineered replication-defective adenovirus type 5 vector to express the SARS-CoV-2 spike protein, which is grown using living cells that were designed and developed at the National Research Council of Canada.
• The National Research Council of Canada’s proprietary HEK293 cell line has been used for the development of numerous biologics, including a previous collaboration with CanSino Biologics on the development of a vaccine against Ebola. To learn more about Dr. Frank Graham’s work on the HEK293 cell line, please visit Foundations of discovery: honouring the work of Canadian researcher Dr. Frank Graham.
• The proposed development timeline for Ad5-nCoV is unprecedented. Generally, vaccines take anywhere from 5 to 15 years to develop.

 

[cath]

Canada working with Chinese company on COVID-19 vaccine
Source:Global Times Published: 2020/5/13 11:43:40
2

A volunteer takes his COVID-19 vaccine injection on March 19 in Wuhan. Photo: Courtesy of Zhu Aobing

A Tianjin-based Chinese vaccine company on Wednesday announced its collaboration with Canadian National Research Council on clinical trials of a novel coronavirus vaccine.

CanSino Biologics Inc, a China-based company of vaccine products for human use, announced that it and the National Research Council of Canada had initiated the collaboration to advance clinical trials for the Recombinant Novel Coronavirus Vaccine (Ad5-nCoV). The clinical trial will start from phase 1/2, aiming for accelerated phase 3 clinical trials to demonstrate the efficacy of the vaccine, according to the company's announcement posted on the Hong Kong Exchanges and Clearing Limited.

China and Canada have been actively engaging in collaboration regarding the COVID-19 pandemic response. The Chinese government's donation of 32 tons of medical aid materials has recently arrived in Canada, and China has been continuing to provide assistance and convenience for the Canadian side in facilitating the country's purchase of medical materials in China, said Zhao Lijian, Chinese Foreign Ministry spokesperson, at a routine press conference on Wednesday.

China is willing to work together with countries around the world including Canada to accelerate research and development of medicines and vaccine for COVID-19 treatment, and make contributions to safeguarding global health security and fighting the pandemic, Zhao noted.

The Ad5-nCoV vaccine has been approved to enter into phase 1 clinical trial in China this March, and results from preclinical animal studies of the vaccine show that the vaccine candidate can induce a strong immune response in animal models. The preclinical animal safety studies demonstrated a good safety profile, according to the company. The company plans to carry out phase 3 clinical trials in more countries.

The vaccine is subject to approval by Health Canada, for which CanSino Biologics is in the process of filing a clinical trial application, according to the National Research Council of Canada.

It is one of only a handful of vaccine candidates in the world against COVID-19 so far approved for initial safety testing in humans, and was the first candidate vaccine to begin conducting phase 2 human clinical trials, the National Research Council of Canada said.

So far, three domestically developed vaccines have entered clinical trials in China.

Global Times

 

[cath]

有兴趣的童鞋可以Google，会从新闻里看出端倪。

 

[cath]

有人这回做冤大头了

 

[cath]

CanSino Biologics and Precision NanoSystems Announce Collaboration to Co-Develop a COVID-19 RNA Vaccine
NEWS PROVIDED BY
Precision Nanosystems
May 20, 2020, 09:00 ET
SHARE THIS ARTICLE

• CanSinoBIO will license in Precision NanoSystems' proprietary RNA vaccine platform technology
  
• Precision NanoSystems will lead RNA vaccine formulation development
  
• CanSinoBIO will lead COVID-19 antigen design, pre-clinical testing and clinical trials

TIANJIN, China and VANCOUVER, May 20, 2020 /CNW/ - CanSino Biologics Inc. (CanSinoBIO, HK6185) and Precision NanoSystems (PNI) today announced a co-development agreement of a mRNA lipid nanoparticle (mRNA-LNP) vaccine against COVID-19. The parties will leverage PNI's proprietary RNA vaccine platform, comprising of lipid nanoparticle delivery system and the NanoAssemblr® manufacturing technology, to rapidly advance a COVID-19 mRNA-LNP vaccine candidate towards human clinical testing and pursuant to regulatory approvals, commercialization in different regions. PNI will be responsible for development of the mRNA-LNP vaccine and CanSinoBIO will be responsible for pre-clinical testing, human clinical trials, regulatory approval and commercialization. CanSinoBIO has rights to commercialize the vaccine product in Asia (except Japan) with PNI retaining rights for rest of the world. The agreement includes undisclosed payments and royalties.
CanSinoBIO is at the forefront of COVID-19 vaccine development efforts with their Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) candidate (the Ad5-nCoV ) currently in phase II clinical trial in China. CanSinoBIO recently announced a collaboration with the National Research Council of Canada to initiate clinical testing of the Ad5-nCoV vaccine candidate in Canada. In parallel to clinical development of Ad5-nCoV, CanSinoBIO wants to join efforts with PNI to develop and commercialize a mRNA-LNP based vaccine. CanSinoBIO's co-founder, chairman and CEO Dr. Xuefeng Yu said, "Our team has been dedicated to developing safe and effective vaccines to fight against the COVID-19 pandemic. Since RNA vaccines are a disruptive technology as they do not require cell culture, utilize synthetic delivery and have a smaller manufacturing footprint, our partnership with PNI to advance a mRNA-LNP vaccine candidate will not only help accelerate the process, but will also potentially revolutionize the vaccine industry."
PNI is a global leader in technologies and solutions for the development and manufacture of nanomedicines. With over 400 NanoAssemblr® systems placed, PNI supports its customers' drug development and manufacturing efforts in the areas of oncology, infectious diseases, and rare diseases. To offer a complete solution for drug developers, PNI has developed a library of lipid formulations for nucleic acid delivery. Dr. Andrew Geall, CSO at PNI and a scientific leader in the field of non-viral delivery of mRNA vaccines said, "PNI has developed lipid formulations that are specifically designed for vaccine applications and we look forward to working with CanSinoBIO to bring the vaccine to patients." PNI's NanoAssemblr® GMP System and manufacturing process, now transferred to several customers, plays a crucial role in scalable, high throughput, reproducible centralized or regional manufacturing of nanomedicines. Dr. James Taylor, co-founder and CEO of PNI said, "We are very excited to partner with CanSinoBIO, an innovative biopharmaceutical company leading the way for COVID-19 vaccine development. We strongly believe PNI's NxGen microfluidic technology and our expertise will enable the rapid development and manufacturing of an effective mRNA-LNP vaccine for COVID-19, and provides the foundation for future pandemic preparedness.
About CanSinoBIO
Incorporated in 2009, CanSinoBIO (6185.HK) commits to research, production and commercialization of innovative vaccines for China and global public health security. It possesses four integrated platform technologies including adenovirus-based vectors, conjugation, protein design and recombination and formulation. As of today, it has established a robust pipeline of 16 vaccines covering 13 diseases, including a globally innovative Ebola virus vaccine approved for marketing in 2017 as well as the investigational Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector).
About Precision NanoSystems Inc.
Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information visit http://www.precisionnanosystems.com.

 

[Rising]

总之，无论哪国疫苗，都不会当先驱。

 

[gigi_co]

总之，无论哪国疫苗，都不会当先驱。

别名白老鼠

 

[Challenger]

我哪国的都不注射，没用，还有风险